Compare Bristol-Myers Squibb Co (BMY) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Vanguard Ultra Short Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while Vanguard Ultra Short Bond ETF trades at $49.67. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Vanguard Ultra Short Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | VUSB | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $65.89 | $50.03 |
52-Week Low | $42.60 | $49.60 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
